EVO News and Press, Evotec SE From 08/06/25

HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, 13 August 2025. The Company is going to ...

HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) regarding the potential sale of Just - Ev...

Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just - Evotec Biologics' ...

2025-07-23 05:43:11 ET I've been covering Evotec ( EVO ) using my small position in this German drug discovery company for exposure to what I view as a volatile but potentially attractive market for returns. The returns so far have been a mixed bag. In my last article, I was positiv...

2025-07-21 06:47:44 ET Evotec ( OTCPK:EVOTF ) announced an update to its fiscal year 2025 revenue guidance, now expecting €760-€800 million (down from €840-€880 million).... Read the full article on Seeking Alpha For further details see: E...

Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platforms High-margin technology license revenues expected to have a stronger impactthan anticipated Significant cost optimizatio...

HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Guidance on R&D expenses and adjusted EBITDA re...

NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury ("AKI") patients, developed as part of a research consortium led by Kidney Research UK The study focuses on 3 clearly defined cohorts: AKI of iatrogeni...

2025-06-15 08:02:19 ET I last took a look at Halozyme Therapeutics ( HALO ) three months ago. However, there has been some major news that could impact the company's longer-term outlook, prompting a revisit. An updated analysis follows below. ... Read the full article ...

2025-06-13 13:45:12 ET Investment Thesis I grant AbCellera Biologics Inc. ( ABCL ) a Hold rating. In my opinion, the critical aspect of the company is whether it will have sufficient financial resources until at least one of its agreements with other firms, or its drug devel...